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S U M M A R Y
Objectives: This study was carried out to evaluate the prevalence of hepatitis delta virus (HDV) among
human immunodeﬁciency virus (HIV)/hepatitis B virus (HBV) co-infected patients from Sa˜o Paulo, in the
Southeast Region of Brazil.
Methods: A total of 3259 HIV patients with serological markers for HBV were initially enrolled in the
study. Among these patients, 154 (4.7%) were hepatitis B surface antigen (HBsAg)-reactive. Serum
samples were obtained from 86 HBsAg-positive patients and were submitted to anti-HDV serological
assay.
Results: One (1.2%) HIV/HBV patient was found to be anti-HDV-positive, and the HDV infection was
conﬁrmed by PCR. Phylogenetic analysis showed that this HDV sequence grouped with other HDV
genotype 1 sequences from Mediterranean European countries, suggesting that this virus has a common
ancestor with HDV from that region. This patient was probably infected by sexual transmission, as he
reported unprotected sexual intercourse with multiple partners over the course of many years but
denied intravenous drug use or any travel to the Brazilian Amazon, an area known to have a high HDV
prevalence.
Conclusions: HDV infection is infrequent in the Southeast Region of Brazil, however there have been a
few cases in this region. HIV/HBV patients are at potential risk for HDV infection, therefore investigations
for the presence of HDV infection must be carried out in these patients.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Fifteen million people are infected with hepatitis delta virus
(HDV) worldwide, and thus it remains a relevant cause of liver-
related illness and death.1
The disease associated with HDV infection is typically more
severe than that due to hepatitis B virus (HBV) infection alone, but
its clinical spectrum ranges from viral asymptomatic carrier to
extremely severe disease.2
Genetic heterogeneity of HDV may inﬂuence the course of
disease in different geographic areas.3,4 The molecular characteri-
zation of HDV prevalent in different regions of the world has
revealed eight groups, designated genotypes 1 to 8 (HDV-1 to HDV-§ This study was presented as a poster at the European Association for the Study
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doi:10.1016/j.ijid.2011.08.0038). HDV-1 is the most widespread worldwide, but is predominant
in Europe, North America, North Africa, and the Middle East; HDV-
2 and HDV-4 are found in East Asia, HDV-3 in the Amazon Basin,
and HDV-5 to HDV-8 were recently identiﬁed in individuals from
Africa.3,5–14
The prevalence of HDV varies greatly depending on the
geographic area. In Brazil, HDV has only been reported in the
Amazon Region, where severe cases of acute and chronic HDV
hepatitis have frequently been described.6,7,15–18
Human immunodeﬁciency virus (HIV), HBV, and HDV share the
same routes of transmission. Among HIV/HBV co-infected patients,
the presence of HDV infection has been associated with an
unfavorable effect on the severity of liver disease by various
authors.19–21 It has been suggested that patients co-infected with
HIV and HBV should be tested for anti-HDV antibodies (IgG and
IgM), particularly if they have lived in an area where HDV is
endemic, and especially in countries where routine immunization
against HBV is not common. Ideally, HDV RNA should be detected
and the viral load level should be determined in patients who are
positive for HDV antibody (anti-HD).22ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Main baseline characteristics of 86 HIV-infected patients with concomitant HBV
infection
Variables
Male gender, n (%) 83 (96.5)
Age (years), mean  SD 42  7.2
Risk factors for HIV transmission
Men who have sex with men, n (%) 64 (74.4)
Intravenous drug use, n (%) 16 (18.6)
Clinical variables
Clinical evidence of advanced liver disease, n (%) 17 (19.8)
Antiretroviral therapy history, n (%) 81 (94.2)
CD4 cell count (cells/ml), mean  SD 545  250
Nadir CD4 cell count (cells/ml), mean  SD 310  140
ALT level, normal, n (%) 54 (62.8)
ALT level >1.5  ULN 32 (37.2)
Anti-HDV 1 (1.2)
Characteristics of HBV
HBeAg-reactive, n (%) 42 (48.8)
HBV DNA < 60 IU/ml, n (%) 50 (58.1)
HBV DNA > 60 IU/ml, n (%) 34 (39.5)
HBV-DNA unknown, n (%) 02 (2.32)
HIV, human immunodeﬁciency virus; HBV, hepatitis B virus; SD, standard
deviation; ALT, alanine aminotransferase; ULN, upper limit of normal; HDV,
hepatitis delta virus; HBeAg, hepatitis B e antigen.
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with hepatitis B surface antigen (HBsAg) ranges from 1.9% to 50%,
depending on the geographic region and the risk group catego-
ry.23–25 Among HIV-infected patients with liver cirrhosis in Spain,
4.6% presented an HDV infection.26
Limited information is available about the seroprevalence of HDV
among HIV/HBV co-infected patients in Brazil.27,28 The aim of this
study was to evaluate the prevalence of HDV in a group of HIV/HBV
co-infected patients in Sa˜o Paulo, in the Southeast Region of Brazil.
2. Materials and methods
2.1. Study design
This cross-sectional study was conducted at two institutions
located in Sa˜o Paulo City Metropolitan Area: one at the AIDS
Outpatient Clinic of the Hospital das Clı´nicas, University of Sa˜o
Paulo School of Medicine and one at the Infectious Diseases
Research Unit, ABC Foundation Medical School Sa˜o Bernardo do
Campo.
2.2. Patient population
The medical records of all patients followed at the study
institutions from May 2006 to November 2007 were reviewed to
identify those who were HIV-infected and HBsAg-reactive. Patients
were selected if they had anti-HIV antibodies detected by ELISA
and conﬁrmed by Western blot together with detectable serum
HBsAg during follow-up. These patients were then invited to a
medical interview, and a blood sample was collected for further
virological analysis. All patients participating in the study signed
an informed consent and the research protocols were approved by
the institutional ethics committees.
Medical records were reviewed to analyze clinical, demograph-
ic, and serological characteristics. Data collected included age, sex,
CD4+ T cell count (current and nadir), use of antiretroviral therapy,
hepatitis B e antigen (HBeAg) reactivity, and HBV viral load
(determined by Cobas Amplicor HBV Monitor Test assay; Roche
Molecular Systems, USA). The use of antiretroviral therapy
(including HBV DNA polymerase inhibitors, such as tenofovir or
lamivudine) was deﬁned as the use of any antiretroviral
medication for >6 months any time prior to baseline.
2.3. Serology
A microparticle enzyme immunoassay (MEIA, Axsym, Abbott
Diagnostic, Germany) was used to detect hepatitis B serological
markers (HBsAg, total antibodies to hepatitis B core antigen (anti-
HBc), antibodies to hepatitis B surface antigen (anti-HBs), HBeAg,
and antibodies to hepatitis B e antigen (anti-HBe)). Anti-HD was
detected by an ELISA (ETI-AB-DELTAK-2, DiaSorin, Italy).
2.4. HDV RNA and HBV DNA detection
RNA was extracted from 140 ml of serum using a QIAamp RNA
Viral Mini Kit (Qiagen, Germany) in accordance with the
manufacturer’s instructions, and HDV RNA was ampliﬁed by
nested polymerase chain reaction (PCR).6 For HBV detection, DNA
was extracted using a QIAamp DNA Mini Kit (Qiagen), and absolute
quantiﬁcation of HBV DNA was performed with an in-house real-
time PCR assay (sensitivity = 50 IU/ml).29
2.5. HDV genotyping
The nested PCR products were puriﬁed using a ChargeSwitch
PCR Clean-Up Kit (Life Technologies, USA). Cycle sequencingreactions of puriﬁed PCR products were performed using a BigDye
Terminator Kit v3.1 (Life Technologies, USA) and the same primers
utilized in the second-round PCR for HDV. The sequences were
read in an automated ABI Prism 377 DNA Sequencer (Applied
Biosystems, USA). The HDV sequence was genotyped by phyloge-
netic reconstructions using reference sequences from each HDV
genotype obtained from GenBank (n = 176). Sequences were
aligned using CLUSTAL_X30 and edited using BioEdit software.31
Bayesian phylogenetic analyses were conducted using the
Markov Chain Monte Carlo (MCMC) simulation implemented in
BEAST v.1.6.1,32 and 10 million generations were sufﬁcient to
obtain the convergence of parameters. The maximum clade
credibility (MCC) tree was obtained from summarizing the 10
000 substitution trees and it was then modiﬁed using a 10% burn-
in using Tree Annotator v.1.6.1.32
3. Results
3.1. Patients
A total of 3259 patients with a conﬁrmed HIV infection and
serological markers for hepatitis B (anti-HBc and HBsAg) were
initially enrolled in the study: 2412 patients from the AIDS
Outpatient Clinic of the Hospital das Clı´nicas and 847 patients from
Sa˜o Bernardo do Campo. Among these patients, 154 (4.7%) were
HBsAg-reactive. Serum samples were obtained from 86 patients;
these patients comprised the study population and underwent
further virological testing for hepatitis delta infection. Table 1
summarizes the main characteristics of the 86 HBsAg-reactive
patients in whom anti-HD testing was performed.
Among 86 HBsAg-reactive patients, only one (1.2%) anti-HD-
positive patient was identiﬁed. HBV DNA was not detected by real-
time PCR in this patient, but the current HDV infection was
conﬁrmed by HDV RNA detection. Phylogenetic analyses showed
that the HDV genotype in this case was HDV-1 and its sequence
was most closely related to some HDV-1 sequences from
Mediterranean European countries (Figure 1).
3.2. Case report
The patient was a 37-year-old male, active homosexual,
originating from Ceara´ (northeast of Brazil) but who had lived
Figure 1. Maximum clade credibility (MCC) tree estimated by Bayesian analysis of 177 partial sequences of delta antigen gene. The sample obtained from the HIV/HBV/HDV
co-infected Brazilian patient is marked with a black triangle. HDV-1 sequences (n = 93) obtained from GenBank are identiﬁed by their accession number followed by
geographic origin. The collapsed clades correspond to the non-HDV-1 genotypes: HDV-2 (n = 9), HDV-3 (n = 36), HDV-4 (n = 13), HDV-5 (n = 6), HDV-6 (n = 3), HDV-7 (n = 6),
HDV-8 (n = 10). The values of posterior probability are shown above their respective key nodes.
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asymptomatic HIV infection and with a hepatitis B virus infection
(HBsAg-positive). At that time, alanine aminotransferase (ALT)
levels were normal. The patient started antiretroviral therapy with
zidovudine, lamivudine, and indinavir in 1999. In 2004, his HIV
viral load was undetectable and CD4 T-cell count was 808/ml, and
he started to present persistently high ALT levels (3–4-fold the
upper limit of normal (ULN)). He was HBeAg-reactive at this time,
but HBV DNA could not be determined, as this test was not
available in the service at that time. He was then submitted to a
liver biopsy, which showed a METAVIR score of F1 A2. After the
liver biopsy, his treatment was changed to tenofovir, atazanavir,
ritonavir, and lamivudine. There was no improvement in ALT
levels, which continued to be elevated (3–10 ULN). HBeAg
continued to be reactive and HBV DNA, which was occasionally
determined from 2007 onwards, was persistently undetectable by
Cobas Amplicor HBV Monitor Test. In 2009, anti-HD serology was
carried out and a reactive result was obtained; the patient was
ﬁnally identiﬁed as HDV-infected.
4. Discussion
HDV infection does not appear to be frequent among patients
co-infected with HIV and HBV in the southeast of Brazil. According
to our data, its presence was found in only one (1.2%) patient
among 86 analyzed.
In Brazil, HDV has been described only in the Amazon Region,
where it is endemic and associated with severe forms of the
disease. In fact, Brazilian studies of HDV prevalence outside
endemic areas are scarce, but these few studies have shown a very
low prevalence: anti-HD was positive in only one out of 81 patients
from Sa˜o Paulo State in a study carried out at the end of the
1980s.33–35
There have been only two studies on the prevalence of HDV
among HIV/HBV patients in Brazil: one of these studies was carried
out in the Western Amazon Region and showed that the HDV
prevalence was 9.4% among HBsAg/anti-HIV-positive patients
from this region, yielding a minimum prevalence of 1.9% overall.27
This prevalence was lower than that found in the general
population from the same region, where anti-HD antibodies
reached 34.4% in HBsAg-positive patients.18,36 Another study
evaluated HDV prevalence among HIV/HBV patients from Mato
Grosso State, in the Central Region of Brazil, and found only one
(2.7%) anti-HD-positive case among 37 HBsAg-positive patients.
HDV infection among HIV/HBV patients in Brazil seems to be less
frequent, even in endemic regions, than in other countries, where
its frequency may reach 50%.37
HDV transmission among HIV/HBV patients has been more
related to a history of intravenous drug use (IVDU) than to high-
risk sexual behavior.37 In the studied population, 18.6% of patients
were IVDU, but no patient in this group was anti-HD-positive. The
HIV/HBV/HDV co-infected patient identiﬁed in this study denied
IVDU, but referred to unprotected sexual intercourse with multiple
partners over the course of many years, indicating that HDV
transmission occurred through sexual contact in this case.
HDV is presently classiﬁed into eight genotypes – HDV-1 to
HDV-8.9,11 Studies on genotype distribution in Brazil have been
restricted to the Amazon Region (Western and Eastern), where
HDV genotype 3 has been found to be prevalent.6,7,38 Nevertheless,
in one Brazilian study, HDV genotype 1 was found in 55% of
the chronically infected patients from the Western Brazilian
Amazon.39
Phylogenetic analysis showed that the HDV isolated from the
HIV patient in our study was genotype 1 (HDV-1) and it grouped
with HDV-1 sequences from Europe. It was not possible to
determine the phylogenetic relationships with the other HDV-1identiﬁed in the Amazon Region because the sequences were not
characterized in that study; the genotypes were characterized by
PCR followed by hybridization with a speciﬁc 32P-labeled
oligonucleotide probe.
Our patient denied any travel to the Amazon Region. As outside
of the Amazon Region HDV prevalence is extremely low or even
absent in Brazil, it is probable that the HDV infection in this case
occurred through contact with someone who had lived in a region
endemic for HDV genotype 1. The sequence from the patient
clustered with other sequences from Mediterranean European
countries, suggesting that this virus has a common ancestor with
HDV from that region. The prevalence of HDV markers in some
cohorts of chronic HBsAg carriers with HIV co-infection in Europe
has varied from 4% to 44%, with HDV genotype 1 being the most
frequent.13,40–44
In the HIV/HBV/HDV co-infected patient identiﬁed in this study,
HBV DNA was undetectable but HDV RNA was positive; this is in
accordance with previous studies, which have shown that HDV
suppresses HBV replication.45 Other studies have shown that most
HIV/HBV/HDV co-infected patients are HDV RNA-positive, which
represents a serious problem as the liver disease is more aggressive
in these patients and the treatment is rarely effective.37 Further-
more, these patients represent an important source for HDV
transmission.
The distribution of infectious agents around the world may be a
dynamic phenomenon. Changes in habits and customs and
mobility between groups may permanently alter the distribution
and occurrence of infections usually restricted to certain geo-
graphic regions. Based on this picture and on the present results,
we recommend that investigations for the presence of HDV
infection be carried out among HIV/HBV co-infected patients,
particularly those with advanced liver disease, even in areas of low
HDV risk. Furthermore, prevention measures should be imple-
mented among HIV patients to avoid HBV and HDV infections, such
as HBV vaccination and the avoidance of high-risk injecting
practices and unprotected sex.
In conclusion, our results demonstrate the presence of HDV
infection among HIV/HBV co-infected patients from a non-
endemic area of Brazil. These ﬁndings indicate the need to
investigate for the presence of HDV infection in HIV/HBV co-
infected patients, particularly those with advanced liver disease,
even in areas of low HDV risk. Furthermore, prevention measures
should be implemented among HIV patients to avoid HBV and HDV
infections, such as HBV vaccination and avoidance of high-risk
injecting practices and unprotected sex.
Acknowledgements
The authors thank the Fundac¸a˜o de Amparo a` Pesquisa do
Estado de Sa˜o Paulo for ﬁnancial support.
Funding: This work was supported by the Fundac¸a˜o de Amparo a`
Pesquisa do Estado de Sa˜o Paulo – FAPESP 2008/57146-9 and 2010/
50081-9.
Ethical approval: This study was approved by the Research
Ethics Committee of the ABC Foundation-Medical School, Sa˜o
Paulo, Brazil.
Conﬂict of interest: The authors declare no conﬂicts of interest.
References
1. Farci P. Delta hepatitis: an update. J Hepatol 2003;39(Suppl 1):S212–9.
2. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, et al. Inﬂuence of
delta infection on severity of hepatitis B. Lancet 1982;2:945–7.
3. Casey JL. Hepatitis delta virus. Genetics and pathogenesis. Clin Lab Med
1996;16:451–64.
4. Rizzetto M, Durazzo M. Hepatitis delta virus (HDV) infections. Epidemiological
and clinical heterogeneity. J Hepatol 1991;13(Suppl 4):S116–8.
M.C. Mendes-Correa et al. / International Journal of Infectious Diseases 15 (2011) e828–e832e8325. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus
that occurs in northern South America. Proc Natl Acad Sci U S A 1993;90:9016–20.
6. Gomes-Gouvea MS, Soares MCP, Carvalho Mello IMV, Brito EM, Moia LJP,
Bensabath G, et al. Hepatitis D and B virus genotypes in chronically infected
patients from the Eastern Amazon Basin. Acta Trop 2008;106:149–55.
7. Gomes-Gouvea MS, Soares MCP, Bensabath G, de Carvalho-Mello IM, Brito EM,
Souza OS, et al. Hepatitis B virus and hepatitis delta virus genotypes in out-
breaks of fulminant hepatitis (Labrea black fever) in the western Brazilian
Amazon region. J Gen Virol 2009;90:2638–43.
8. Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis
delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J
Gen Virol 2001;82:2709–18.
9. Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth
major clade for hepatitis delta virus. Emerg Infect Dis 2006;12:1447–50.
10. Lee CM, Changchien CS, Chung JC, Liaw YF. Characterization of a new genotype II
hepatitis delta virus from Taiwan. J Med Virol 1996;49:145–54.
11. Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, Drugan T, et al. Molecular
phylogenetic analyses indicate a wide and ancient radiation of African hepatitis
delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol
2004;78:2537–44.
12. Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Miyazato S, Kinjo F, et al.
Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa,
Japan. J Med Virol 1999;58:366–72.
13. Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Casey JL.
Geographic distribution and genetic variability of hepatitis delta virus genotype
I. Virology 1997;234:160–7.
14. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and
viremia of hepatitis B and D viruses are associated with outcomes of chronic
hepatitis D patients. Gastroenterology 2006;130:1625–35.
15. Bensabath G, Dias LB. [Labrea hepatitis (Labrea black fever) and other fulminant
forms of hepatitis in Sena Madureira, Acre and Boca do Acre, Amazonas, Brazil].
Rev Inst Med Trop Sao Paulo 1983;25:182–94.
16. Bensabath G, Hadler SC, Soares MC, Fields H, Dias LB, Popper H, et al. Hepatitis
delta virus infection and Labrea hepatitis. Prevalence and role in fulminant
hepatitis in the Amazon Basin. JAMA 1987;258:479–83.
17. Parana R, Vitvitski L, Pereira JE. Hepatotropic viruses in the Brazilian Amazon: a
health threat. Braz J Infect Dis 2008;12:253–6.
18. Viana S, Parana R, Moreira RC, Compri AP, Macedo V. High prevalence of
hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. Am
J Trop Med Hyg 2005;73:808–14.
19. Buti M, Jardi R, Allende H, Cotrina M, Rodriguez F, Viladomiu L, et al. Chronic
delta hepatitis: is the prognosis worse when associated with hepatitis C virus
and human immunodeﬁciency virus infections? J Med Virol 1996;49:66–9.
20. Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, et al. Interactions
between human immunodeﬁciency virus-1, hepatitis delta virus and hepatitis
B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology
1992;15:578–83.
21. Soriano V, Garcia-Samaniego J, Gutierrez M, Bravo R, Gonzalez-Lahoz J. High
morbidity and mortality of chronic viral liver disease in HIV-infected individu-
als in Spain. J Infect 1994;28:100–2.
22. Cross TJ, Taylor CB, Harrison PM. Viral hepatitis in HIV infection. N Engl J Med
2007;357:90. author reply 91.
23. Fainboim H, Gonzalez J, Fassio E, Martinez A, Otegui L, Eposto M, et al. Preva-
lence of hepatitis viruses in an anti-human immunodeﬁciency virus-positive
population from Argentina. A multicentre study. J Viral Hepat 1999;6:53–7.
24. Filippini P, Coppola N, Scolastico C, Rossi G, Battaglia M, Onofrio M, et al. Hepatitis
viruses and HIV infection in the Naples area. Infez Med 2003;11:139–45.
25. Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, et al. Impact of
hepatitis D virus infection on the long-term outcomes of patients with hepatitis
B virus and HIV coinfection in the era of highly active antiretroviral therapy: a
matched cohort study. Clin Infect Dis 2007;44:988–95.
26. Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, et al.
Survival of HIV-infected patients with compensated liver cirrhosis. AIDS
2010;24:745–53.27. Braga WS, da Costa Castilho M, dos Santos IC, Moura MA, Segurado AC. Low
prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among
patients with human immunodeﬁciency virus or acquired immunodeﬁciency
syndrome in the Brazilian Amazon basin. Rev Soc Bras Med Trop 2006;39:
519–22.
28. de Almeida Pereira RA, Mussi AD, de Azevedo e Silva VC, Souto FJ. Hepatitis B
virus infection in HIV-positive population in Brazil: results of a survey in the
state of Mato Grosso and a comparative analysis with other regions of Brazil.
BMC Infect Dis 2006;6:34.
29. Sitnik R, Paes A, Mangueira CP, Pinho JR. A real-time quantitative assay for
hepatitis B DNA virus (HBV) developed to detect all HBV genotypes. Rev Inst
Med Trop Sao Paulo 2010;52:119–24.
30. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X
windows interface: ﬂexible strategies for multiple sequence alignment aided
by quality analysis tools. Nucleic Acids Res 1997;25:4876–82.
31. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:
95–8.
32. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling
trees. BMC Evol Biol 2007;7:214.
33. Ferraz ML, Vilela MP, Silva AE, Paiva ER. [Serological markers for hepatitis B
virus and delta antibody in Brazilian male homosexuals]. Rev Paul Med
1985;103:228–30.
34. Oliveira ML, Bastos FI, Telles PR, Yoshida CF, Schatzmayr HG, Paetzold U,
et al. Prevalence and risk factors for HBV, HCV and HDV infections among
injecting drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res 1999;32:
1107–14.
35. Strauss E, Gayotto LC, da Silva LC, Alves VA, Carrilho F, Chamone DA, et al.
Unexpected low prevalence of delta antibodies in the east Amazon region and
Sao Paulo: evidence for regional differences in the epidemiology of delta
hepatitis virus within Brazil. Trans R Soc Trop Med Hyg 1987;81:73–4.
36. Fonseca JC, Simonetti SR, Schatzmayr HG, Castejon MJ, Cesario AL, Simonetti JP.
Prevalence of infection with hepatitis delta virus (HDV) among carriers of
hepatitis B surface antigen in Amazonas State, Brazil. Trans R Soc Trop Med Hyg
1988;82:469–71.
37. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-
infection. Antiviral Res 2010;85:303–15.
38. Kiesslich D, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, et al.
Inﬂuence of hepatitis B virus (HBV) genotype on the clinical course of disease in
patients coinfected with HBV and hepatitis delta virus. J Infect Dis 2009;199:
1608–11.
39. Parana R, Kay A, Molinet F, Viana S, Silva LK, Salcedo JM, et al. HDV genotypes in
the Western Brazilian Amazon region: a preliminary report. Am J Trop Med Hyg
2006;75:475–9.
40. Arribas JR, Gonzalez-Garcia JJ, Lorenzo A, Montero D, Ladron de Guevara C,
Montes M, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in
HIV-infected patients in Madrid, Spain. AIDS 2005;19:1361–5.
41. Chlabicz S, Grzeszczuk A, Lapinski TW, Prokopowicz D, Panasiuk A. Search for
hepatitis delta virus (HDV) infection in hepatitis C patients in north-eastern
Poland. Comparison with anti-HDV prevalence in chronic hepatitis B. Eur J
Epidemiol 2003;18:559–61.
42. Cotrina M, Buti M, Jardi R, Quer J, Rodriguez F, Pascual C, et al. Hepatitis delta
genotypes in chronic delta infection in the northeast of Spain (Catalonia). J
Hepatol 1998;28:971–7.
43. Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predomi-
nance of hepatitis delta virus genotype I among chronically infected Italian
patients. Hepatology 1997;25:728–34.
44. Zhang YY, Hansson BG. Introduction of a new hepatitis agent in retrospect:
genetic studies of Swedish hepatitis D virus strains. J Clin Microbiol
1996;34:2713–7.
45. Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, et al.
Viral interference between hepatitis B, C, and D viruses in dual and triple
infections in HIV-positive patients. J Acquir Immune Deﬁc Syndr 2009;51:
574–81.
